Previous 10 | Next 10 |
The following slide deck was published by Abiomed, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Image source: The Motley Fool. Abiomed Inc (NASDAQ: ABMD) Q2 2020 Earnings Call Oct 31, 2019 , 8:00 a.m. ET Operator Continue reading
Abiomed, Inc. (ABMD) Q2 2020 Earnings Conference Call October 31, 2019, 08:00 AM ET Company Participants Ingrid Goldberg - Director of IR Mike Minogue - Chairman, President and CEO Todd Trapp - VP and CFO Conference Call Participants Raj Denhoy - Jefferies Jayson Bedford ...
Shares of Abiomed (NASDAQ: ABMD) had jumped 11.9% higher as of 11:30 a.m. EDT on Thursday. The heart pump maker announced its fiscal 2019 second-quarter results before the market opened. Abiomed reported Q2 revenue of $205 million, up 13% year over year. It posted earnings of $13.1 million,...
Abiomed (NASDAQ: ABMD ): Q2 Non-GAAP EPS of $1.03 beats by $0.10 ; GAAP EPS of $0.28. Revenue of $204.97M (+12.8% Y/Y) misses by $1.48M . Shares +0.5% PM. Press Release More news on: Abiomed, Inc., Earnings news and commentary, Healthcare stocks news
Three cardiac surgeons at Cleveland Clinic , Hackensack Meridian Health and Cedars-Sinai Medical Center are the first in the United States to implant Abiomed’s (NASDAQ: ABMD) newest heart pump, the Impella 5.5 with SmartAssist . Ed Soltesz, MD, Mark Anderson, MD, and Danny Ramz...
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported second quarter fiscal 2020 revenue of $205.0 million, an increase of 13% compared to revenue of $181.8 million for the same period of fiscal 2019. Operating income was ...
Nearly two years of real-world outcomes data on Abiomed’s (NASDAQ: ABMD) Impella RP heart pump shows that when physicians followed the FDA’s approved protocol for Impella RP use they achieved 72% patient survival and 88% native heart recovery. These results, from the Impella...
Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, October 31, 2019, the Company will release financial results for the second quarter of fiscal 2020. The Company will host a conference call to discuss the results on Thursday, October 31, 2019, at 8:00 a.m. ET. Michael R. Minogue, Cha...
Abiomed (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, announces the 1,000th patient has been treated with the Impella heart pump in Japan. The Impella 2.5 and Impella 5.0 heart pumps are approved for the treatment of drug-resistant acute heart failure and ...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...